Ocugen

Historical price data

Ocugen is a patient-centric biotech focused on developing transformative therapies for blinding retinal diseases and infectious diseases. Its core innovation is a modifier gene therapy platform that aims to reset retinal homeostasis, offering a single treatment for multiple genetic mutations. The company is advancing a diversified pipeline, with a Phase 3 asset in retinitis pigmentosa and strategic partnerships to bolster its development and commercial capabilities. Ocugen's strategy leverages deep ophthalmology and gene therapy expertise to address significant unmet medical needs.

A first-in-class, gene-agnostic modifier gene therapy platform using AAV vectors to deliver nuclear hormone receptors (NR2E3, RORA) to reset retinal homeostasis, aiming to treat multiple genetic mutations with a single therapy.